<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715882</url>
  </required_header>
  <id_info>
    <org_study_id>BL612-CBLB502</org_study_id>
    <nct_id>NCT02715882</nct_id>
  </id_info>
  <brief_title>Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer</brief_title>
  <official_title>Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLab 612 LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cleveland BioLabs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioLab 612 LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of
      CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses
      and Regimens
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability evaluation as measured by adverse events and assessed as changes in vital signs and clinical laboratory measurements, physical examination findings and ECG readings</measure>
    <time_frame>Baseline to up to 14 days after the drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of immune cells change in tumor by H&amp;E and ICH staining</measure>
    <time_frame>On Day 7 (Surgery day) after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of levels of cytokine IL-6 in blood by multiplex assays</measure>
    <time_frame>Baseline to up to 7 days after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of levels of cytokine IL-8 in blood by multiplex assays</measure>
    <time_frame>Baseline to up to 7 days after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of levels of cytokine IL-10 in blood by multiplex assays</measure>
    <time_frame>Baseline to up to 7 days after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of levels of cytokine G-CSF in blood by multiplex assays</measure>
    <time_frame>Baseline to up to 7 days after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of levels of cytokine TNFа in blood by multiplex assays</measure>
    <time_frame>Baseline to up to 7 days after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific T-cell responses measured by ELIspot</measure>
    <time_frame>Baseline to up to 14 days after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titer to CBLB502 as measured by ELISA</measure>
    <time_frame>Baseline and on day 14 after the drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood leukocytes by FACS</measure>
    <time_frame>Baseline to up to 7 days after the drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1 injection of CBLB502 0.35 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 injection of CBLB502 0.45 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 injections of CBLB502 0.35 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 injections of CBLB502 0.45 μg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBLB502</intervention_name>
    <arm_group_label>1 injection of CBLB502 0.35 μg/kg</arm_group_label>
    <arm_group_label>1 injection of CBLB502 0.45 μg/kg</arm_group_label>
    <arm_group_label>2 injections of CBLB502 0.35 μg/kg</arm_group_label>
    <arm_group_label>2 injections of CBLB502 0.45 μg/kg</arm_group_label>
    <other_name>Entolimod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1 injection of CBLB502 0.35 μg/kg</arm_group_label>
    <arm_group_label>1 injection of CBLB502 0.45 μg/kg</arm_group_label>
    <arm_group_label>2 injections of CBLB502 0.35 μg/kg</arm_group_label>
    <arm_group_label>2 injections of CBLB502 0.45 μg/kg</arm_group_label>
    <other_name>PBS</other_name>
    <other_name>Phosphate buffer saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written Patient Informed Consent for participation in the study

          2. Men and women in the age above 18 years

          3. Patients with confirmed diagnosis of colorectal cancer, indication to scheduled
             surgery for primary tumor removal

          4. Should not have any previous anticancer therapy

          5. Patient's life expectancy more than 3 months

          6. ECOG performance status 0-1

          7. Adequate hepatic and renal function:

               -  Total bilirubin ≤1.5 upper limit of normal (ULN)),

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN,
                  regardless of the presence of liver metastases,

               -  Creatinine ≤2 x ULN

          8. Adequate cardiac function including:

               -  LVEF ≥45 by echocardiogram (ECHO) or multi gated acquisition scan,

               -  12-lead electrocardiogram (ECG) with normal tracing or non-clinically significant
                  changes that do not require medical intervention,

               -  QTcB interval QT (QTc by Bazett's formula) &lt; 470 msec and no history of Torsades
                  des Pointes or other symptomatic QTcB abnormality,

               -  Absence of orthostatic hypotonia

          9. Negative testing for serological markers of HIV-infection, viral hepatitis В and С,
             syphilis

         10. Content to use barrier contraception methods by male/female patient and his/her
             partner in the study period

        Exclusion Criteria:

          1. Inability to obtain written Informеd consent for participation in the study

          2. History of cardiovascular abnormalities including any conditions stated below:

               -  Myocardial infarction/stroke for the last 6 months,

               -  Stable abnormalities in regional contractility,

               -  Cardiac failure (NYHA functional class III-IV),

               -  Confirmed cardiomyopathy,

               -  Clinically significant arrhythmias including any conditions stated below:

                    -  QT prolongation syndrome,

                    -  History of II or III-degree AV-block,

                    -  Bradycardia (HR &lt; 50 beats per min.) or tachycardia (HR &gt;100 beats per min.)

               -  Blood pressure abnormalities:

                    -  2 degree uncontrolled arterial hypertension (systolic blood pressure &gt; 160
                       mm Hg or diastolic blood pressure &gt; 105 mm Hg),

                    -  Hypotension (systolic blood pressure &lt; 90 mm Hg)

          3. History of severe allergic, systemic and other oncologic diseases

          4. Decompensated diabetes mellitus with glycolated hemoglobin level (HbA1c) &gt; 7%

          5. Administration of drug products with evident effect on immune system for previous 3
             months prior screening (including corticosteroids. Remark: Topical agents (e.g. for
             rash treatment), inhalation aerosols (e.g. for treatment of broncho-obstructive
             diseases), eye drops and agents for local administration (e.g. to joint cavity) is
             allowed

          6. Participation in other clinical studies or administration of study products for 30
             days prior screening, or persisting adverse reactions of the study product

          7. Patients that have not taken CBLB502

          8. Patients with hypersensitivity/allergy to CBLB502 or excipients of the drug product;
             NSAID (including ibuprofen)

          9. Pregnant or lactating women

         10. History of salmonellosis

         11. Body mass &gt; 88 kg; no obesity which means BMI in the range 18.5-25 kg/m2 for women and
             22-27 kg/m2 for men

         12. Men and women of childbearing age which do agree to use double contraception method,
             oral contraception or abstain from sex contacts throughout the study

         13. Alcohol abuse, drug abuse and any other medical, psychological and social reasons
             which may, in accordance with the investigator, affect patient's participation in the
             study, may prevent adequate assessment of the study results

         14. Any conditions which are unstable or may endanger patient's safety and/or affect
             his/her adherence to the investigator instruction

         15. Any patient is not able or willing to cooperate with the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergei I. Achkasov, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution &quot;State Scientific Center of Coloproctology named after A.N. Ryzhikh&quot; Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolay V. Kislov, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Institution of Health of the Yaroslav Region &quot;Regional Clinical Oncology Hospital&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei V. Odintcov, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution &quot;Central Clinical Hospital with polyclinic&quot; Department of Presidential Affairs of the Russian Federation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;State Scientific Center of Coloproctology named after A.N. Ryzhikh&quot; Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>TLR5</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

